Full history for every metric is available with a Kvantra account
BioSenic S.A. (BIOS.BR)
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Operating profit | €m | -1 | -1 | |||||
| Net profit | €m | -12 | -1 | -2 | -29 | -5 | 21 | 21 |
| EPS reported | € | 0.03 | 0.03 | |||||
| Operating cashflow per share | € | -0.00 | -0.00 | |||||
| Capex per share | € | 0.00 | 0.00 | |||||
| FCF per share | € | 0.00 | 0.00 | |||||
| Free cash flow | €m | 0 | 0 | |||||
| Net debt | €m | 4 | 4 | |||||
| Book value equity | €m | -2 | -2 | |||||
| Book value per share | € | -0.00 | -0.00 | |||||
| Number of shares | m | 652.86 | 651.96 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 0.07 | - | |||||
| P/B LTM | x | -0.77 | -0.67 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | 0.00 | 0.00 | |||||
| EV/EBITDA LTM | x | -3.96 | -3.07 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | 1428.6% | 1605.4% | |||||
| FCF Yield | % | 0.00% | 0.00% | |||||
| Quality | ||||||||
| ROE | % | -1070.2% | -163.81% | |||||
| ROIC | % | -71.55% | -72.69% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.00 | 0.00 | |||||
| Net Debt/EBITDA | x | -2.82 | -2.28 | |||||
| EBIT/Net interest | x | -189.00 | -192.00 | |||||
| Net debt/market cap | % | 248.87% | 286.20% | |||||
| Net debt/Equity | x | -1.91 | -1.91 | |||||
| Gross debt/equity | x | -1.95 | -1.95 | |||||
Company overview
BioSenic S.A., a biotechnology company located in Mont-Saint-Guibert, Belgium, is dedicated to progressing clinical therapeutic solutions. The firm utilizes two primary technology platforms: an innovative allogeneic cell and gene therapy system featuring distinct bone marrow-derived mesenchymal stromal cells designed for convenient on-site hospital storage; and an Arsenic Trioxide platform. The latter is deployed in immuno-oncology to target illnesses such as graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's leading experimental drug, ALLOB, is currently undergoing a Phase IIb clinical trial for patients with complicated tibial fractures.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
BioSenic S.A. (BIOS.BR)
BioSenic S.A., a biotechnology company located in Mont-Saint-Guibert, Belgium, is dedicated to progressing clinical therapeutic solutions. The firm utilizes two primary technology platforms: an innovative allogeneic cell and gene therapy system featuring distinct bone marrow-derived mesenchymal stromal cells designed for convenient on-site hospital storage; and an Arsenic Trioxide platform. The latter is deployed in immuno-oncology to target illnesses such as graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's leading experimental drug, ALLOB, is currently undergoing a Phase IIb clinical trial for patients with complicated tibial fractures.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free